Public Reimbursement for Biosimilar Byooviz™ to Treat Serious Retinal Disorders Now Secured in Four Provinces and Two National Benefits Programs
Ontario and New Brunswick among latest jurisdictions to reimburse biosimilar of anti-VEGF ranibizumab, improving patient access to treatment for certain retinal diseases Toronto, ON — Biogen Canada Inc. is pleased to… Read More




